G2GBIO Inc. (456160.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
29,700.00 KRW
Market cap
487.69 bn KRW
P/E (2025)
–
P/S (2025)
1,152.74
Dividend yield
0.00 %
Net margin
-2,857.07 %
Return on equity (ROE)
-20.72 %
Return on assets (ROA)
-17.84 %

G2GBIO Inc. financials

Fiscal year20242025
Revenue768.93 m KRW423.07 m KRW
Gross profit190.33 m KRW-33.48 m KRW
Operating income-10.76 bn KRW-12.20 bn KRW
EBIT-80.81 bn KRW-11.38 bn KRW
Net income-83.25 bn KRW-12.09 bn KRW
Diluted EPS – continuing operations-5,172.03 KRW-736.11 KRW

Full history since 2024, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About G2GBIO Inc.

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company's pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer's disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.